Drug · CHEMBL771
CYCLOSERINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CYCLOSERINE. Drugs and targets, record CHEMBL771. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL771
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 3 of its 46 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases46
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 46Source Open Targets
See all 46 diseasesTrials130
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01404208 | 2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD | 206 | 2017-02-27 | d-cycloserine | Its name | ClinicalTrials.gov | |
| NCT01352637 | Enhancing Exposure Therapy for Post Traumatic Stress Disorder (PTSD): Virtual Reality and Imaginal Exposure With a Cognitive Enhancer | Phase 3 | 192 | 2019-07-02 | d-cycloserine | Its name | ClinicalTrials.gov |
| NCT00790868 | Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder | Phase 2 | 180 | 2018-03-07 | d-cycloserine | Its name | ClinicalTrials.gov |
| NCT00515879 | Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia | Phase 3 | 169 | 2015-07-23 | D-cycloserine | Its name | ClinicalTrials.gov |
| NCT00633984 | D-Cycloserine Enhancement of Exposure in Social Phobia | Phase 4 | 169 | 2014-05-14 | d-cycloserine | Its name | ClinicalTrials.gov |
| NCT00356278 | D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD | Phase 2/3 | 156 | 2014-11-19 | d-cycloserine | Its name | ClinicalTrials.gov |
| NCT02066792 | Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder | Early phase 1 | 152 | 2020-06-09 | d-cycloserine | Its name | ClinicalTrials.gov |
| NCT01399866 | Cognitive Remediation With D-Cycloserine | Phase 3 | 150 | 2015-05-04 | d-cycloserine | Its name | ClinicalTrials.gov |
| NCT01411774 | D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD) | Phase 3 | 142 | 2018-01-23 | d-cycloserine | Its name | ClinicalTrials.gov |
| NCT00674570 | Veteran Stress and Learning Study | Phase 4 | 111 | 2019-05-30 | d-cycloserine | Its name | ClinicalTrials.gov |
1 to 10 of 130
See all 130 trialsComparisons in its trials50
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| D-cycloserine vs Placebo: deaths from any cause | 0 of 88 | 0 of 92 | 180 | NCT00790868 | Trial comparisons |
| D-cycloserine vs Placebo: serious adverse events | 1 of 88 | 1 of 92 | 180 | NCT00790868 | Trial comparisons |
| D-cycloserine-augmented CBT vs Placebo-augmented CBT: serious adverse events | 0 of 87 | 0 of 82 | 169 | NCT00515879 | Trial comparisons |
| Cognitive Behavioral Therapy + DCS vs Cognitive Behavioral Therapy + Placebo: serious adverse events | 0 of 87 | 0 of 82 | 169 | NCT00633984 | Trial comparisons |
| D-Cycloserine vs Sugar Pill: serious adverse events | 0 of 70 | 0 of 72 | 142 | NCT01404208 | Trial comparisons |
| Cognitive-behavioral Therapy Plus Pill Placebo vs Cognitive-behavioral Therapy Plus D-cycloserine: deaths from any cause | 0 of 72 | 0 of 70 | 142 | NCT01411774 | Trial comparisons |
| Cognitive-behavioral Therapy Plus Pill Placebo vs Cognitive-behavioral Therapy Plus D-cycloserine: serious adverse events | 0 of 72 | 0 of 70 | 142 | NCT01411774 | Trial comparisons |
| D-cycloserine vs Placebo: serious adverse events | 0 of 34 | 1 of 33 | 67 | NCT01086475 | Trial comparisons |
| D-cycloserine vs Placebo: serious adverse events | 0 of 30 | 1 of 32 | 62 | NCT01399866 | Trial comparisons |
| DCS and Cognitive Behavioral Therapy vs Placebo and Cognitive Behavioral Therapy: serious adverse events | 0 of 29 | 0 of 30 | 59 | NCT01067846 | Trial comparisons |
1 to 10 of 50
See all 50 comparisons in its trialsPapers from its trials80
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials26
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| 1-Back Task | 7 | 1 | ConductCognition |
| Trail Making Test B | 7 | 1 | ConductCognition |
| Implicit Association Test (IAT) | 6 | 1 | ConductCognition |
| 2-Back Task | 6 | 1 | ConductCognition |
| Choice Reaction Time | 5 | 0 | ConductCognition |
| Short Story Recall | 5 | 2 | ConductCognition |
| Symbol Coding | 5 | 1 | ConductCognition |
| Card Sorting Test (Berg) | 4 | 1 | ConductCognition |
| Verbal Learning | 4 | 2 | ConductCognition |
| Continuous Performance Test | 2 | 0 | ConductCognition |
1 to 10 of 26
See all 26 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL771
GET https://conductscience.org/api/drugs/v1/CHEMBL771/diseases?page=2